莫格利珠单抗治疗蕈样真菌病和Sézary综合征专家推荐意见(2025年版)  

Expert recommendations on mogamulizumab in treatment of mycosis fungoides and Sézary syndrome(2025 version)

作　　者：中国医疗保健国际交流促进会肿瘤内科学分会 石远凯 刘鹏 李小秋 Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care;Shi Yuankai(不详;Department of Medical Oncology,Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100021,China)

机构地区：[1]不详 [2]国家癌症中心、国家肿瘤临床医学研究中心、中国医学科学院北京协和医学院肿瘤医院内科、抗肿瘤分子靶向药物临床研究北京市重点实验室,北京100021

出　　处：《白血病.淋巴瘤》2025年第1期8-15,共8页Journal of Leukemia & Lymphoma

摘　　要：蕈样真菌病(MF)和Sézary综合征(SS)均为非霍奇金淋巴瘤中的皮肤型T细胞淋巴瘤,因二者在T细胞起源、临床特征和治疗效果等方面存在明显差异,目前被认为属于两种不同性质的疾病,在2022年修订的第5版世界卫生组织造血淋巴肿瘤分类中被归入不同的亚型。莫格利珠单抗是靶向CC趋化因子受体4的人源化单克隆抗体,2022年10月11日获得中国国家药品监督管理局附条件批准用于治疗既往接受过至少1次系统性治疗的复发或难治SS或晚期(Ⅲ、Ⅳ期)MF成年患者。为帮助广大医师更合理地应用莫格利珠单抗,中国医疗保健国际交流促进会肿瘤内科学分会组织专家编写了该推荐意见。Mycosis fungoides(MF)and Sézary syndrome(SS)are both cutaneous T-cell lymphomas within the category of non-Hodgkin lymphoma.Because there are differences in the T-cell origin,clinical characteristics and treatment efficacy,they are considered to be two distinct disease entities and are classified into different subtypes in the 5th revised edition of World Health Organization classification of hematopoietic lymphoid tumors in 2022.Mogamulizumab is humanized monoclonal antibody targeting CC chemokine receptor 4,and it was conditionally approved by China National Medical Products Administration for the treatment of adult patients with relapsed or refractory SS or advanced(stageⅢorⅣ)MF who had received at least one previous systemic therapy on October 11,2022.In order to help physicians apply mogamulizumab more rationally,the Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care organized experts to compile this expert recommendation.

关 键 词：蕈样真菌病 SÉZARY综合征 莫格利珠单抗 专家推荐意见 

分 类 号：R73[医药卫生—肿瘤]